Fig. 1From: Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis resultsKaplan–Meier plot of PFS by investigator assessment (a) and IIR (b). CI, confidence interval; IIR, independent imaging review; PFS, progression-free survivalBack to article page